Clinical utility of digital technologies in Parkinson’s disease

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • Björn Falkenburger - , Department of Neurology (Author)
  • Alessandra Fanciulli - , Innsbruck Medical University (Author)
  • Monika Pötter-Nerger - , University of Hamburg (Author)
  • Thilo van Eimeren - , University of Cologne (Author)
  • Joseph Classen - , Leipzig University (Author)
  • Günter Höglinger - , Ludwig Maximilian University of Munich, Munich Cluster for Systems Neurology (SyNergy) (Author)
  • Christoph Redecker - , Bielefeld University (Author)
  • Jürgen Winkler - , Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • Jochen Klucken - , University of Luxembourg (Author)

Abstract

Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson’s disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.

Details

Original languageEnglish
JournalJournal of Neural Transmission
Publication statusE-pub ahead of print - 12 Nov 2025
Peer-reviewedYes

External IDs

PubMed 41222710